One type of vaccine for non-small cell lung cancer (NSCLC) has been clinically proven to be a three-step vaccine, and has been successfully introduced to overseas markets with a good impact on non-small cell lung cancer.

The vaccine, an anti-idiotypic monoclonal antibody, allows lung cancer patients to develop a strong immune response to certain glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with optimal supportive treatment, lung cancer vaccines can improve the survival rate of relapsed and advanced (IIIB / IV) non-small cell lung cancer patients.

In contrast to many mammals, including monkeys, we could not detect the presence of NeuGcGM3 gangliosides in normal human tissues and fluids. However, NeuGcGM3 ganglioside is highly expressed in certain human cancer cells. In non-small cell lung cancer samples, more than 90% of non-small cell lung cancers detected ganglioside. Therefore, NeuGcGM3 ganglioside can be used as a powerful target for lung cancer vaccines. 

The immune system can produce antibodies against the specificity of the first antigen after generating specific antibodies to the antigen and can control the immune system inside. Following lung cancer vaccination, antibodies to the antigen can be stimulated and recorded as Ab1. These Ab1 antibodies are capable of producing a series of anti-idiotype antibodies designated Ab2. The unique form of this particular antibody is integrated into the antigen binding site of Ab1, which can cause a general antigen-specific immune response. Thus, vaccination with an Ab2 antibody can promote the production of Ab3 (an anti-anti-idiotypic antibody) which in turn recognizes the original antigen recognized by Abl. This type of specific Ab2 antibody stimulates the immune system to induce protective immunity against tumor antigens.

It has been clinically proven that lung cancer vaccines are well tolerated and safe. Many common side effects occur only locally (injection site) and are mild and short-lived. Even if the vaccine is given after the patient's condition deteriorates, the overall survival rate of this patient will increase accordingly.